About this trial
The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL) and works as well as the standard dose of radiation therapy. The researchers will see if VLDRT works against cancer in the area that is currently affected by cancer and if the therapy prevents new spots of lymphoma from developing. The researchers will also compare VLDRT with the standard dose of radiation therapy to see if VLDRT causes fewer side effects.
Radiation therapy uses beams of intense energy to kill cancer cells. Standard doses of radiation therapy can cause short- and long-term side effects. Researchers think VLDRT may be as effective as standard doses, and, because VLDRT uses less radiation, researchers think VLDRT may cause fewer side effects than standard doses.
Eligibility criteria
Qualifiers
Follicular lymphoma
WHO 5th Edition
Classic follicular lymphoma (cFL)
Follicular lymphoma with uncommon features (uFL)
Disqualifiers
Prior radiation to site(s) needing treatment
Follicular lymphoma, grade 3B (ICC) or Follicular large B cell lymphoma (FLBL by WHO 5th edition criteria)
Patients planned to receive concurrent systemic therapy (including oral steroids) for their lymphoma
Patient has cutaneous only iNHL defined as primary cutaneous B-cell lymphoma, primary cutaneous follicle center lymphoma, cutaneous marginal zone lymphoma or unspecified indolent lymphoma of the skin
Trial design
Treatments tested in this trial
- Radiation (Standard)
- Radiation (Very low dose)
Treatment groups
Sponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
The Leukemia and Lymphoma Society
Collaborator